Hilsenbeck S - Search Results

1

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.

Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, Hilsenbeck S, Osborne CK, Rimawi M. Nangia J, et al. Among authors: hilsenbeck s. JAMA. 2017 Feb 14;317(6):596-605. doi: 10.1001/jama.2016.20939. JAMA. 2017. PMID: 28196254 Clinical Trial.

2

Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.

Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CK. Reddy KB, et al. Among authors: hilsenbeck sg. Cell Growth Differ. 1994 Dec;5(12):1275-82. Cell Growth Differ. 1994. PMID: 7696176

3

Prognostic factors: rationale and methods of analysis and integration.

Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Clark GM, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1994;32(1):105-12. doi: 10.1007/BF00666211. Breast Cancer Res Treat. 1994. PMID: 7819579 Review.

4

Heat shock proteins and drug resistance.

Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Fuqua SA, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1994;32(1):67-71. doi: 10.1007/BF00666207. Breast Cancer Res Treat. 1994. PMID: 7819588 Review.

5

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

6

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Brown RW, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Mar;2(3):585-92. Clin Cancer Res. 1996. PMID: 9816207

7

The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.

Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA. Oesterreich S, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Jul;2(7):1199-206. Clin Cancer Res. 1996. PMID: 9816288

8

Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Hilsenbeck SG, et al. Breast Cancer Res Treat. 1998;52(1-3):227-37. doi: 10.1023/a:1006133418245. Breast Cancer Res Treat. 1998. PMID: 10066085

9

Significance of axillary lymph node metastasis in primary breast cancer.

Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Jatoi I, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1999 Aug;17(8):2334-40. doi: 10.1200/JCO.1999.17.8.2334. J Clin Oncol. 1999. PMID: 10561295

10

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Liu Y, et al. Oncogene. 2002 Oct 31;21(50):7680-9. doi: 10.1038/sj.onc.1205883. Oncogene. 2002. PMID: 12400010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

379 results

Search Page

Filters